| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Taro Kishi, Tadashi Nosaka, Kenji Sakuma, Makoto Okuya, Nakao Iwat. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacology reports. vol 40. issue 3. 2021-08-27. PMID:32767739. |
considering that the efficacy results of the japan lurasidone phase 3 trials for acute schizophrenia were inconsistent, we conducted a systematic review and a random-effect model network meta-analysis of those trials to examine whether lurasidone was beneficial for the treatment of japanese patients with acute schizophrenia. |
2021-08-27 |
2023-08-13 |
Not clear |
| Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Kentaro Takai, Teruhiko Higuch. Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. Neuropsychiatric disease and treatment. vol 17. 2021-08-26. PMID:34429604. |
safety and effectiveness of lurasidone in patients with schizophrenia: a 12-week, open-label extension study. |
2021-08-26 |
2023-08-13 |
Not clear |
| Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Kentaro Takai, Teruhiko Higuch. Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. Neuropsychiatric disease and treatment. vol 17. 2021-08-26. PMID:34429604. |
the goal of this study was to evaluate the safety and effectiveness of lurasidone among patients with schizophrenia in a 12-week open-label extension study. |
2021-08-26 |
2023-08-13 |
Not clear |
| Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Tadashi Nosaka, Teruhiko Higuch. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry and clinical neurosciences. 2021-08-18. PMID:33890388. |
efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled study. |
2021-08-18 |
2023-08-13 |
Not clear |
| Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Tadashi Nosaka, Teruhiko Higuch. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry and clinical neurosciences. 2021-08-18. PMID:33890388. |
the aim of this study was to evaluate the efficacy of lurasidone in acute schizophrenia in japan and other countries. |
2021-08-18 |
2023-08-13 |
Not clear |
| Ilena Pochiero, Fabrizio Calisti, Alessandro Comandini, Alessandra Del Vecchio, Isabella Costamagna, Maria Teresa Rosignoli, Agnese Cattaneo, Sasikiran Nunna, Ilaria Peduto, Franca Heiman, Hsiu-Ching Chang, Chi-Chang Chen, Christoph Correl. Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. International journal of general medicine. vol 14. 2021-08-10. PMID:34366678. |
impact of lurasidone and other antipsychotics on body weight: real-world, retrospective, comparative study of 15,323 adults with schizophrenia. |
2021-08-10 |
2023-08-13 |
Not clear |
| Vishwas P Pardhi, Swaran Flor. Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder. Biopharmaceutics & drug disposition. vol 41. issue 8-9. 2021-08-09. PMID:33080060. |
stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder. |
2021-08-09 |
2023-08-13 |
Not clear |
| Varsha Pokharkar, Smita Suryawanshi, Vividha Dhapte-Pawa. Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics. Drug delivery and translational research. vol 10. issue 4. 2021-08-02. PMID:31858442. |
this delivery strategy was employed for lurasidone, a clinically usfda-approved neurotherapeutic molecule in bipolar disorders and schizophrenia treatments. |
2021-08-02 |
2023-08-13 |
Not clear |
| Christoph Correll, Michael Tocco, Andrei Pikalov, Jay Hsu, Robert Goldma. Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127098. |
efficacy of lurasidone in antipsychotic-naive vs. antipsychotic-exposed adolescents with schizophrenia: post-hoc analysis of a two-year, open-label study. |
2021-07-23 |
2023-08-13 |
Not clear |
| Christoph Correll, Michael Tocco, Andrei Pikalov, Jay Hsu, Robert Goldma. Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127098. |
the aim of this analysis was to evaluate the long-term efficacy of lurasidone in antipsychotic-naive adolescents with schizophrenia. |
2021-07-23 |
2023-08-13 |
Not clear |
| Mrunali R Patel, Rashmin B Patel, Shivam D Thakore, Ajay B Solank. Brain targeted delivery of lurasidone HCl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia. Pharmaceutical development and technology. vol 25. issue 8. 2021-06-17. PMID:32432956. |
brain targeted delivery of lurasidone hcl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia. |
2021-06-17 |
2023-08-13 |
Not clear |
| Mrunali R Patel, Rashmin B Patel, Shivam D Thakore, Ajay B Solank. Brain targeted delivery of lurasidone HCl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia. Pharmaceutical development and technology. vol 25. issue 8. 2021-06-17. PMID:32432956. |
this investigation aimed to design, develop, and optimize intranasal nanoemulsion for brain targeted delivery of lurasidone hydrochloride for the management and treatment of schizophrenia. |
2021-06-17 |
2023-08-13 |
Not clear |
| Harika Modugula, Anoop Kuma. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS & neurological disorders drug targets. vol 19. issue 2. 2021-06-14. PMID:32124704. |
risk analysis of lurasidone in patients with schizophrenia and bipolar depression. |
2021-06-14 |
2023-08-13 |
Not clear |
| Harika Modugula, Anoop Kuma. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS & neurological disorders drug targets. vol 19. issue 2. 2021-06-14. PMID:32124704. |
in conclusion, lurasidone is a novel and efficacious pharmacological treatment for bipolar depression and schizophrenia. |
2021-06-14 |
2023-08-13 |
Not clear |
| Preeya J Patel, Christian Weidenfeller, Andrew P Jones, Jens Nilsson, Jay Hs. Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study. Neurology and therapy. vol 10. issue 1. 2021-06-08. PMID:33098548. |
long-term assessment of lurasidone in schizophrenia: post hoc analysis of a 12-month, double blind, active-controlled trial and 6-month open-label extension study. |
2021-06-08 |
2023-08-13 |
Not clear |
| Preeya J Patel, Christian Weidenfeller, Andrew P Jones, Jens Nilsson, Jay Hs. Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study. Neurology and therapy. vol 10. issue 1. 2021-06-08. PMID:33098548. |
a post hoc analysis of a double-blind (db) active control trial and an open-label extension (ole) study was conducted to evaluate the long-term effects of lurasidone in patients with schizophrenia. |
2021-06-08 |
2023-08-13 |
Not clear |
| Yuan Feng, Jianguo Shi, Lili Wang, Xia Zhang, Yunlong Tan, Jingyuan Zhao, Yuping Ning, Shiping Xie, Xuejun Liu, Qi Liu, Keqing Li, Xiaoliang Wang, Lehua Li, Xiufeng Xu, Wei Deng, Xiaoyan Luo, Gang Wan. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. Psychiatry and clinical neurosciences. vol 74. issue 6. 2021-05-31. PMID:31823444. |
randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. |
2021-05-31 |
2023-08-13 |
Not clear |
| Marco Andrea Riva, Umberto Albert, Sergio de Filippis, Antonio Vita, Domenico De Berardi. Identification of clinical phenotypes in schizophrenia: the role of lurasidone. Therapeutic advances in psychopharmacology. vol 11. 2021-05-26. PMID:34025981. |
identification of clinical phenotypes in schizophrenia: the role of lurasidone. |
2021-05-26 |
2023-08-13 |
Not clear |
| Marco Andrea Riva, Umberto Albert, Sergio de Filippis, Antonio Vita, Domenico De Berardi. Identification of clinical phenotypes in schizophrenia: the role of lurasidone. Therapeutic advances in psychopharmacology. vol 11. 2021-05-26. PMID:34025981. |
lurasidone is a second-generation antipsychotic drug representing a novel and useful clinical tool for the management of schizophrenia. |
2021-05-26 |
2023-08-13 |
Not clear |
| Christoph U Correll, Robert L Findling, Michael Tocco, Andrei Pikalov, Ling Deng, Robert Goldma. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study -- CORRIGENDUM. CNS spectrums. 2021-05-17. PMID:33998439. |
safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study -- corrigendum. |
2021-05-17 |
2023-08-13 |
Not clear |